Tirzepatide.

Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight loss) are brand-name tirzepatide made by Eli Lilly. Compounded tirzepatide is made by a state-licensed 503A pharmacy to a custom formula. Both contain tirzepatide as the active ingredient, but compounded medications are not FDA-approved. CLYR offers both options so you can choose what works best for you.

Most patients see meaningful appetite reduction within the first 2 weeks. Visible weight loss typically begins by week 4 to 6. The most significant results come over 6 to 12 months of consistent treatment combined with sustainable eating and movement habits.

The most common side effects are gastrointestinal: nausea, diarrhea, constipation, and reduced appetite. These usually peak in the first 2 weeks of each dose increase and subside as your body adjusts. Less common but serious side effects include pancreatitis, gallbladder issues, and (in rare cases) thyroid tumors in patients with a personal or family history of medullary thyroid cancer or MEN-2.

Anyone with a personal or family history of medullary thyroid carcinoma or MEN-2, severe gastroparesis, active pancreatitis, or a history of severe allergic reaction to tirzepatide. Pregnant or breastfeeding women should also avoid it. Your provider will screen for all of these at consultation.

Tirzepatide can interact with insulin and sulfonylureas (raising hypoglycemia risk), oral contraceptives (slowing absorption due to delayed gastric emptying), and warfarin. Always tell your provider everything you take, including over-the-counter and supplements.

Without ongoing treatment, appetite typically returns and most patients regain weight unless they have built sustainable habits. Many patients use tirzepatide as a long-term tool combined with lifestyle changes. Your provider can also help you taper safely if you choose to stop.

Yes. Every CLYR order ships free with expedited cold-chain delivery. No subscription minimums, no surprise charges.